📰 Active Controlled Crossover Study News

Active Controlled Crossover Study News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Active Controlled Crossover Study. Real-time updates on events, politics, business and more.

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103

August 23, 2022

Completion of Clinical Portion Represents Critical Milestone Towards CommercializationNasal Opioid Abuse Being Explored for PF614Data From Trial Expected in September 2022SAN DIEGO, CA / ACCESSWIRE / August

United States Lynn Kirkpatrick Ensysce Biosciences Glen Apseloff Shannon Devine Ohio Clinical Trials Inc

Source: finanznachrichten.de

Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103

August 23, 2022

Press release content from Accesswire. The AP news staff was not involved in its creation.

United States Lynn Kirkpatrick Ensysce Biosciences Glen Apseloff Shannon Devine Ohio Clinical Trials Inc

Source: apnews.com

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study

July 13, 2022

~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~SAN DIEGO, CA / ACCESSWIRE / July 13, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage

San Diego United States Lynn Kirkpatrick Ensysce Biosciences Glen Apseloff Shannon Devine

Source: finanznachrichten.de

Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study

May 23, 2022